SANGAMO THERAPEUTICS, INC. (SGMOQ) Total liabilities 2016–2025
SANGAMO THERAPEUTICS, INC. (SGMOQ) total liabilities at each fiscal year-end, per SEC filings.
$74.0MFY2025 · since FY2016: $21.7M → $74.0M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $74.0M | -6.2% |
| FY2024 | $78.9M | -4.3% |
| FY2023 | $82.4M | -69.2% |
| FY2022 | $267.6M | -22.8% |
| FY2021 | $346.6M | -21.4% |
| FY2020 | $441.2M | +115.4% |
| FY2019 | $204.8M | -8.2% |
| FY2018 | $223.1M | +125.8% |
| FY2017 | $98.8M | +355.6% |
| FY2016 | $21.7M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice
More SGMOQ financial trends
SGMOQ RevenueSGMOQ Net incomeSGMOQ Net marginSGMOQ Gross profitSGMOQ Gross marginSGMOQ Operating incomeSGMOQ Operating marginSGMOQ Operating cash flowSGMOQ Free cash flowSGMOQ Capital expendituresSGMOQ Return on equitySGMOQ Stock buybacksSGMOQ Dividends paidSGMOQ Total assetsSGMOQ Shareholders’ equitySGMOQ overview →